Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Lawlor

Podiatrist, Foot & Ankle Surgery Ft Myers, FL Doctor of Podiatric Medicine

NPI 1336123231 CMS profile 151356

8851 Boardroom Cir, Ft Myers, FL 33919

Open in the dashboard

General payments

$72,467

381 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Lawlor of Ft Myers, FL is reported in the CMS Open Payments database as having received $72,467 across 381 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19,106 60
2024 General $30,253 102
2023 General $10,843 69
2022 General $8,071 83
2021 General $1,058 14
2020 General $1,158 19
2019 General $1,978 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Lawlor
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to John Lawlor were reported at $19,106. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year John Lawlor Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $1,978 $389 $118–$1,406 $163
2020 $1,158 $191 $62–$691 $114
2021 $1,058 $329 $104–$1,341 $132
2022 $8,071 $419 $125–$1,611 $149
2023 $10,843 $377 $128–$1,164 $160
2024 $30,253 $394 $134–$1,168 $164
2025 $19,106 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Aroa Biosurgery Incorporated $65,693 286 payments
  2. Biocomposites Inc $2,022 39 payments
  3. Boston Scientific Corporation $1,616 15 payments
  4. W. L. Gore & Associates, Inc. $456 3 payments
  5. Integra LifeSciences Corporation $380 4 payments
  6. PolyMedics Innovations Inc $327 4 payments
  7. Organogenesis Inc. $299 6 payments
  8. Acell, Inc. $219 3 payments
  9. Medtronic, Inc. $196 4 payments
  10. Reprise Biomedical, Inc. $172 1 payment
  11. Other $1,088 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $31,200 11 payments
  2. Food and Beverage $21,191 353 payments
  3. Consulting Fee $17,729 7 payments
  4. Travel and Lodging $2,347 10 payments
Products named General payments · program years 2019–2025
  1. Stimulan $2,022 39 payments
  2. INTEGRA FLOWABLE WOUND MATRIX $271 3 payments
  3. PRIMATRIX $271 3 payments
  4. INTEGRA WOUND MATRIX (THIN) $271 3 payments
  5. INTEGRA MESHED BILAYER WOUND MATRIX $271 3 payments
  6. INTEGRA DERMAL REGENERATION TEMPLATE $271 3 payments
  7. Puraply $252 5 payments
  8. GENERAL - VASCULAR INTERVENTION $218 2 payments
  9. ANGIOJET $207 2 payments
  10. GORE EXCLUDER AAA Endoprosthesis $188 1 payment
  11. Other $3,163 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

413

Median for Podiatry: 160

Drug cost

$6,396

Median for Podiatry: $2,368

Branded share of claims

4.6%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 151 $2,954
Pregabalin Generic 42 $650
Ciclopirox Generic 11 $499
Doxycycline Hyclate Generic 37 $417
Colchicine Generic 19 $407
Allopurinol Generic 44 $284
Ammonium Lactate Generic 13 $259
Duloxetine Hcl Generic 16 $252
Ciprofloxacin Hcl Generic 20 $212
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 19 $184

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$520,406

Of which drugs: $199,961

Medicare patients

594

Average age 76

Services billed

6,825

262 women, 332 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Diabetes 54%
Ischemic heart disease 51%
Chronic kidney disease 42%
Heart failure 35%
Atrial fibrillation 35%
Depression 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Helicoll, per square centimeter Q4164 Office 11 163 $199,850
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 113 859 $78
Injection, methylprednisolone acetate, 1 mg J1010 Office 19 21 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $91
$91 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

381 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record